2025 has seen a wave of positive anti-fibrosis advances. From Agomab’s Phase 2a results in fibrostenosing Crohn’s, Boehringer’s Phase 3 IPF data, Stanford’s TGF-β work in cardiovascular fibrosis, to over […]

With the release of the draft ICH M15 guidelines and the FDA’s move to phase out animal testing, regulatory change is accelerating, solidifying Model-Informed Drug Development (MIDD) as a critical, […]

3rd LNP Characterization & Analytical Development Summit De-Risk Regulatory Submissions Through Smarter LNP Characterization Curated in collaboration with leading analytical scientists and key LNP stakeholders, the 3rd LNP Characterization & […]

The Only Industry-Dedicated Summit for Advancing Myeloid Cell Therapies in Oncology, Inflammation and Beyond... Uniting leading experts from pharma, biotech, and academia, the 7th Myeloid-Directed Therapies Summit is the definitive […]

The 9th Dermatology Drug Development Summit is the definitive industry-led forum bringing together a driven community of experts pioneering innovative drug discovery and clinical strategies to improve long-term outcomes for patients with […]

Returning for its third year, the Donor Selection & Cell Source Summit is the only industry-dedicated forum focused exclusively on the strategic and scientific challenges of donor selection and cell […]

Diving Into the Complement Cascade to Explore Intervention Points, Harnessing Biomarker Strategies to Identify Optimal Patient Populations, & Exploring the Therapeutic Opportunity from Rare Disease to Inflammation to Autoimmune Disease. […]

Recognized as the industry’s leading forum for cell therapy analytical, quality control, assay, and CMC professionals, the 7th Cell Therapy Analytical Development Summit, returns to Boston to provide the expertise […]

RNA-targeting small molecules are rapidly emerging as a powerful therapeutic reality. From modulating splicing to directly binding RNAs, these molecules offer a revolutionary approach to treating previously undruggable diseases across […]

The 2nd Innovation in Obesity Therapeutics Summit will return to San Diego this December. Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly and Boehringer Ingelheim, […]

With major FDA changes already reshaping the regulatory landscape - and global agencies ramping up scrutiny - 2025 is a pivotal year for cell and gene therapy regulatory professionals. With […]

The World’s Only Industry-Specific Forum on AI-Oriented Skills-Centric Workforce Transformation in Life Sciences Most roles in biopharma organizations will undergo an AI-driven transformation in the coming years. But exactly how […]

Navigate New FDA Leadership, Harness AI-Powered Submissions & Align Technical Innovation with the Latest Nonclinical, Clinical & CMC Guidance to Overcome Regulatory Challenges and Accelerate Your Path to Clinic & […]

The 6th Gene Therapy for Ophthalmic Disorders Summit returns to Raleigh, North Carolina, as the leading industry forum dedicated to accelerating the development of gene therapies for both rare and common eye […]

Ever since the field-defining studies in Nature Medicine and the New England Journal demonstrated that cell therapies could hold lasting potential in lupus and beyond, the field has grown from […]

With the European oncology market increasingly focused on emerging modalities, highlighted by AbbVie’s recent licensing agreement with Ichnos Glenmark Innovation for their trispecific antibody, Boehringer Ingelheim’s partnership with Tempus to advance their cancer pipeline […]

As biopharma organizations decrease their budgets and move away from a recruitment-centric approach, the need to develop existing talent to fill key technical skills gaps has never been more mission […]

With the launch of the FDA’s Project Optimus, and the evolving clinical pharmacology guidelines for ADCs, the need to identify an optimal clinical dose that balances safety with efficacy has […]

Unlocking Safer, More Efficient Delivery to Targeted Brain Regions by Advancing Direct, & Systemic Delivery to the CNS Via TfR1 & Beyond Despite milestones such as Roche’s Trontinemab Brainshuttle™ achieving […]

The race to deliver safe, effective non-opioid pain therapeutics has never been more urgent - or more achievable. After decades of setbacks, the field is achieving long-awaited progress with recent […]

With global cases of AMD, DME, and glaucoma rapidly increasing, ophthalmic drug R&D is accelerating to meet urgent unmet needs. However, poor treatment adherence, invasive procedures, and adverse side effects […]

2025 is proving to be a landmark year for RNAi. From Alnylam’s first approval in hemophilia to Novartis’ $1.2 billion acquisition of Avidity Biosciences and GSK diving into COPD with […]

Molecular glues are leading the charge in the race to drug the previously undruggable, and 2025 has seen continued investment and partnerships driving innovation in this field. Returning as the industry’s only […]

The 5th mRNA-Based Therapeutics Summit Europe is the leading European industry-focused forum dedicated to accelerating the safe, scalable, and clinically impactful development of messenger RNA (mRNA) medicines. Returning for its […]

The 6th Age-Related Disease Therapeutics Summit is the leading global meeting dedicated to advancing therapies that target the biology of aging and age-related diseases. Over three days, the summit brings […]

Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity in tumor modeling. As the FDA phases out animal testing […]

Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as α-synuclein, neuroinflammation, and metabolic targets. Against the backdrop of a globally surging patient population, the […]

The past decade has transformed liquid biopsy, which was previously just an exciting concept, into a routine, commercially viable technology that is saving patients’ lives and transforming clinical trials. Uniting […]

With Novartis committing $750M to ProFound Therapeutics to discover new cardiovascular candidates, and Illumina acquiring SomaLogic for $425 to expand its proteomic capabilities just this year alone, the increasing recognition […]

The Longest Standing & Pre-Eminent European ADC Forum 16th World ADC London | 800+ Industry Attendees | 240+ Companies | 110+ Global Speakers With traditional ADCs now fulfilling their potential […]